http://www.wrightslaw.com/

http://www.wrightslaw.com/

Main FX Resource

Roche mGluR5 Antagonist RO4917523 Date Posted: 2/21/2011, Last Updated: 4/1/2011

The randomized, double-blind, placebo-controlled clinical study sponsored by Roche Pharmaceuticals is testing an mGluR5 antagonist, which decreases mGluR5 activity in the brain and may improve learning and cognition. Its name is RO4917523; more information is available at clinicaltrials.gov. A phase I trial of this drug was conducted last year in adults without fragile X syndrome, and no serious adverse events were noted. The current trial will assess safety and tolerability of this medicine, as well as its effects on learning, mood, and behavior. Eight visits over 11 weeks are required, and the study involves multiple blood draws. Participants will get physical examinations and detailed testing of learning and behavior. Some sites are currently recruiting; others will begin soon - please check clinicaltrials.gov The study sites are: Emory University Fragile X Clinical Trials Unit, Atlanta, GA Dr. Jeannie Visootsak, principal investigator Contact either Krista Charen at 404-778-8479 or kharkre@emory.edu or Lisa Shubeck at 404-778-8478 or lshubec@emory.edu Rush University Medical Center, Chicago, IL Dr. Elizabeth Berry-Kravis, principal investigator Contact trial/research intake coordinator Crystal Hervey at 312-942-7250 or Crystal_Hervey@rush.edu Riley Hospital for Children Indianapolis, IN Dr. Craig Erickson, principal investigator Contact a member of Dr. Erickson's team at 317-278-9766 or kidpsych@iupui.edu Vanderbilt University Medical Center, Nashville, TN Dr. Jeremy Veenstra-VanderWeele, principal investigator Contact Clinical Trials Associate Hannah Benneyworth at 615-936-3288 or Martha.H.Benneyworth@vanderbilt.edu MIND Institute, University of CA at Davis Dr. Randi Hagerman, principal investigator Contact Sarah Coffey at 916-703-0281 or sarah.coffey@ucdmc.ucdavis.edu

Roche mGluR5 Antagonist RO4917523 Date Posted: 2/21/2011, Last Updated: 4/1/2011

The randomized, double-blind, placebo-controlled clinical study sponsored by Roche Pharmaceuticals is testing an mGluR5 antagonist, which decreases mGluR5 activity in the brain and may improve learning and cognition. Its name is RO4917523; more information is available at clinicaltrials.gov. A phase I trial of this drug was conducted last year in adults without fragile X syndrome, and no serious adverse events were noted. The current trial will assess safety and tolerability of this medicine, as well as its effects on learning, mood, and behavior. Eight visits over 11 weeks are required, and the study involves multiple blood draws. Participants will get physical examinations and detailed testing of learning and behavior. Some sites are currently recruiting; others will begin soon - please check clinicaltrials.gov The study sites are: Emory University Fragile X Clinical Trials Unit, Atlanta, GA Dr. Jeannie Visootsak, principal investigator Contact either Krista Charen at 404-778-8479 or kharkre@emory.edu or Lisa Shubeck at 404-778-8478 or lshubec@emory.edu Rush University Medical Center, Chicago, IL Dr. Elizabeth Berry-Kravis, principal investigator Contact trial/research intake coordinator Crystal Hervey at 312-942-7250 or Crystal_Hervey@rush.edu Riley Hospital for Children Indianapolis, IN Dr. Craig Erickson, principal investigator Contact a member of Dr. Erickson's team at 317-278-9766 or kidpsych@iupui.edu Vanderbilt University Medical Center, Nashville, TN Dr. Jeremy Veenstra-VanderWeele, principal investigator Contact Clinical Trials Associate Hannah Benneyworth at 615-936-3288 or Martha.H.Benneyworth@vanderbilt.edu MIND Institute, University of CA at Davis Dr. Randi Hagerman, principal investigator Contact Sarah Coffey at 916-703-0281 or sarah.coffey@ucdmc.ucdavis.edu

Roche mGluR5 Antagonist RO4917523 Date Posted: 2/21/2011, Last Updated: 4/1/2011

The randomized, double-blind, placebo-controlled clinical study sponsored by Roche Pharmaceuticals is testing an mGluR5 antagonist,...    (which decreases mGluR5 activity in the brain and may improve learning and cognition. Its name is RO4917523; more information is available at clinicaltrials.gov.) A phase I trial of this drug was conducted last year in adults without fragile X syndrome, and no serious adverse events were noted. The current trial will assess safety and tolerability of this medicine, as well as its effects on learning, mood, and behavior. Eight visits over 11 weeks are required, and the study involves multiple blood draws. Participants will get physical examinations and detailed testing of learning and behavior. Some sites are currently recruiting; others will begin soon - please check clinicaltrials.gov The study sites are: Emory University Fragile X Clinical Trials Unit, Atlanta, GA Dr. Jeannie Visootsak, principal investigator Contact either Krista Charen at 404-778-8479 or kharkre@emory.edu or Lisa Shubeck at 404-778-8478 or lshubec@emory.edu MIND Institute, University of CA at Davis Dr. Randi Hagerman, principal investigator Contact Sarah Coffey at 916-703-0281 or sarah.coffey@ucdmc.ucdavis.edu Rush University Medical Center, Chicago, IL Dr. Elizabeth Berry-Kravis, principal investigator Contact trial/research intake coordinator Crystal Hervey at 312-942-7250 or Crystal_Hervey@rush.edu Riley Hospital for Children Indianapolis, IN Dr. Craig Erickson, principal investigator Contact a member of Dr. Erickson's team at 317-278-9766 or kidpsych@iupui.edu Vanderbilt University Medical Center, Nashville, TN Dr. Jeremy Veenstra-VanderWeele, principal investigator Contact Clinical Trials Associate Hannah Benneyworth at 615-936-3288 or Martha.H.Benneyworth@vanderbilt.edu

Semantic Versioning

Not relevant to FX, apparently.  Authored by Tom Preston-Werner
This could enighten the mind or boggle the mind, depending on the mind:

Semantic Versioning, which regards software code.